Phenotypic and genotypic characterization of fecal Escherichia coli isolates with decreased susceptibility to fluoroquinolones:: Results from a large hospital-based surveillance initiative

被引:27
作者
Lautenbach, Ebbing
Fishman, Neil O.
Metlay, Joshua P.
Mao, Xiangqun
Bilker, Warren B.
Tolomeo, Pam
Nachamkin, Irving
机构
[1] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Div Infect Dis, Dept Med, Philadelphia, PA 19104 USA
[3] Univ Penn, Sch Med, Div Gen Internal Med, Dept Med, Philadelphia, PA 19104 USA
[4] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA
[5] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
[6] Univ Penn, Sch Med, Ctr Educ & Res Therapeut, Philadelphia, PA 19104 USA
[7] Dept Vet Affairs, Philadelphia, PA USA
关键词
D O I
10.1086/503046
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The prevalence of fecal colonization with Escherichia coli that has reduced susceptibility to fluoro-quinolones is unknown. A detailed characterization of such isolates is limited. Methods. We conducted 3 annual fecal surveillance initiatives at 2 hospitals from 2002 to 2004. All E. coli isolates with reduced susceptibility to fluoroquinolones ( minimum inhibitory concentration [ MIC] to levofloxacin, >= 0.125 mu g/mL) were identified. We characterized gyrA and parC mutations and organic solvent tolerance (OST). Isolates were compared using pulsed-field gel electrophoresis. Results. Of 789 fecal samples, 149 (18.9%) revealed E. coli with reduced susceptibility to fluoroquinolones. Of 149 isolates, 102 (68.5%) had a MIC >= 8 mu g/mL, 138 (92.6%) had >= 1 gyrA mutation, 101 (67.8%) had >= 1 parC mutation, and 59 (39.6%) demonstrated OST. Isolates with a MIC >= 8 versus < 8 mu g/mL had more target mutations (median, 3 vs. 1; P <.001) and more often exhibited OST (51% vs. 15%; P <.001). Of 149 isolates, 144 (96.6%) demonstrated a MIC >= 16 mu g/mL to nalidixic acid. The prevalence of OST differed across study years (P =.01). There was no clonal spread of isolates. Conclusions. Colonization by E. coli with reduced fluoroquinolone susceptibility is common, and fluoroquinolone-resistance characteristics differ significantly over time. Resistance to nalidixic acid may be useful in the identification of E. coli with early resistance mutations.
引用
收藏
页码:79 / 85
页数:7
相关论文
共 37 条
[11]   New uses for new and old quinolones and the challenge of resistance [J].
Hooper, DC .
CLINICAL INFECTIOUS DISEASES, 2000, 30 (02) :243-254
[12]   Prevalence of plasmid-mediated quinolone resistance [J].
Jacoby, GA ;
Chow, N ;
Waites, KB .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (02) :559-562
[13]   Mechanisms of resistance to quinolones [J].
Jacoby, GA .
CLINICAL INFECTIOUS DISEASES, 2005, 41 :S120-S126
[14]  
Kleinbaum DG., 1982, EPIDEMIOLOGIC RES
[15]   Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections:: The role of inadequate empirical antimicrobial therapy [J].
Lautenbach, E ;
Metlay, JP ;
Bilker, WB ;
Edelstein, PH ;
Fishman, NO .
CLINICAL INFECTIOUS DISEASES, 2005, 41 (07) :923-929
[16]   Test characteristics of perirectal and rectal swab compared to stool sample for detection of fluoroquinolone-resistant Escherichia coli in the gastrointestinal tract [J].
Lautenbach, E ;
Harris, AD ;
Perencevich, EN ;
Nachamkin, I ;
Tolomeo, P ;
Metlay, JP .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (02) :798-800
[17]   Longitudinal trends in fluoroquinolone resistance among enterobacteriaceae isolates from inpatients and outpatients, 1989-2000: Differences in the emergence and epidemiology of resistance across organisms [J].
Lautenbach, E ;
Strom, BL ;
Nachamkin, I ;
Bilker, WB ;
Marr, AM ;
Larosa, LA ;
Fishman, NO .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (05) :655-662
[18]   Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae [J].
Lautenbach, E ;
Strom, BL ;
Bilker, WB ;
Patel, JB ;
Edelstein, PH ;
Fishman, NO .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (08) :1288-1294
[19]   Characterization of clinical isolates of Escherichia coli showing high levels of fluoroquinolone resistance [J].
Lehn, N ;
StowerHoffmann, J ;
Kott, T ;
Strassner, C ;
Wagner, H ;
Kronke, M ;
SchneiderBrachert, W .
JOURNAL OF CLINICAL MICROBIOLOGY, 1996, 34 (03) :597-602
[20]   Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections [J].
Lindgren, PK ;
Karlsson, Å ;
Hughes, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (10) :3222-3232